Crispr Therapeutics AG (CRSP) revenue breakdown
By product, Collaboration Revenue is the largest at 94% of fiscal 2024 revenue, growing 183% a year over 4 years.
Revenue by product
Fiscal years, as Crispr Therapeutics AG reports them in its 10-K filings; fiscal 2024 total $37M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $543,000 | $913M | $436,000 | $370M | $35M | 94% |
| Grant Revenue | $176,000 | $2M | $762,000 | $1M | $2M | 6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CRSP.
Open CRSP in InvestinglyQuestions
Where does Crispr Therapeutics AG make its money?
In fiscal 2024, by product: Collaboration Revenue $35M, Grant Revenue $2M.
From Crispr Therapeutics AG's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.